Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Bioventures 2014 L.P. Mpm Sells 57,225 Shares

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Bioventures 2014 L.P. Mpm sold 57,225 shares of the business’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $0.87, for a total value of $49,785.75. Following the sale, the insider owned 4,867,341 shares of the company’s stock, valued at $4,234,586.67. The trade was a 1.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Thursday, December 4th, Bioventures 2014 L.P. Mpm sold 83,230 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.97, for a total transaction of $80,733.10.
• On Tuesday, December 2nd, Bioventures 2014 L.P. Mpm sold 59,277 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total transaction of $52,756.53.
• On Monday, December 1st, Bioventures 2014 L.P. Mpm sold 60,917 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total transaction of $57,261.98.
• On Friday, November 28th, Bioventures 2014 L.P. Mpm sold 20,277 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.99, for a total transaction of $20,074.23.
• On Wednesday, November 26th, Bioventures 2014 L.P. Mpm sold 60,733 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.98, for a total value of $59,518.34.
• On Tuesday, November 25th, Bioventures 2014 L.P. Mpm sold 42,533 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.92, for a total value of $39,130.36.
• On Monday, November 24th, Bioventures 2014 L.P. Mpm sold 88,802 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total value of $87,025.96.
• On Friday, November 21st, Bioventures 2014 L.P. Mpm sold 64,331 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.83, for a total value of $53,394.73.
• On Thursday, November 20th, Bioventures 2014 L.P. Mpm sold 41,152 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.89, for a total value of $36,625.28.
• On Wednesday, November 19th, Bioventures 2014 L.P. Mpm sold 66,324 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.94, for a total value of $62,344.56.

Werewolf Therapeutics Stock Down 1.4%

NASDAQ HOWL traded down $0.01 on Friday, reaching $0.98. The company had a trading volume of 67,889 shares, compared to its average volume of 502,483. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 3.87. Werewolf Therapeutics, Inc. has a 1 year low of $0.60 and a 1 year high of $2.38. The firm has a 50-day moving average of $1.40 and a 200-day moving average of $1.33. The firm has a market capitalization of $47.67 million, a PE ratio of -0.61 and a beta of 0.74.

Werewolf Therapeutics (NASDAQ:HOWL) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. On average, equities research analysts anticipate that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on HOWL. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. JMP Securities cut their price target on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 21st. Bank of America reduced their price target on Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Zacks Research downgraded Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.75.

Hedge Funds Weigh In On Werewolf Therapeutics

Hedge funds have recently bought and sold shares of the company. Jane Street Group LLC bought a new stake in Werewolf Therapeutics in the second quarter valued at about $409,000. Citadel Advisors LLC bought a new position in Werewolf Therapeutics during the 3rd quarter worth approximately $304,000. Vanguard Group Inc. grew its position in shares of Werewolf Therapeutics by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after acquiring an additional 109,796 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Werewolf Therapeutics in the 2nd quarter worth approximately $113,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Werewolf Therapeutics in the 2nd quarter valued at approximately $92,000. 64.84% of the stock is currently owned by institutional investors and hedge funds.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.